Trials Sponsors Conditions Drugs Pricing

Conditions

Hypoxia Insulin Resistance Obstructive Sleep Apnea

Keywords

Obstructive Sleep ApneaHypoxiaInsulin Resistance

Outcome Measures

Primary Outcomes (2)

Fractional De Novo Lipogenesis (DNL, %)
The percent of newly synthesized fatty acids (DNL, %) will be measured using a stable isotope (deuterated water) and mass spectrometry.
8 weeks
Liver fat Fraction (%)
Magnetic resonance will be used to measure liver and pancreatic fat fraction (%)
8 weeks

Secondary Outcomes (2)

Insulin secretion rate (picomol/min)
8 weeks
Total fat mass (grams)
8 weeks

Study Arms (2)

OSA with hypoxia

People with obstructive sleep apnea and hypoxia before and after treatment with continuous positive airway pressure

Device: Continuous Positive Airway Pressure

OSA without hypoxia

People with obstructive sleep apnea and without hypoxia before and after treatment with continuous positive airway pressure

Device: Continuous Positive Airway Pressure

Interventions

Continuous Positive Airway PressureDevice

CPAP is a noninvasive treatment for sleep apnea

OSA with hypoxiaOSA without hypoxia

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age19 Years - 100 Years

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Participants will be recruited from the UCSF Clinical Sleep Medicine Laboratory. Patients seen by UCSF sleep medicine physicians (including Dr. Krystal \[Lab Co-Director\]) in sleep clinic and those who are referred for polysomnography (PSG) for OSA and for whom the physician has provided approval to be approached, will be contacted by the study coordinator and offered the opportunity to be screened to participate in the study. The study coordinator will review the consent form with the prospective volunteers and will ask for their approval to have their PSG data reviewed by Dr. Krystal, who will determine if the participants meet PSG entry criteria for participation in the study and if found to qualify, to be contacted by phone.

You may qualify if:

Sponsors & Collaborators

University of California, San Francisco
Otherlead
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIHcollaborator

Study Sites (1)

University of California San Francisco

San Francisco, California, 94110, United States

Biospecimen

Retention: SAMPLES WITH DNA

Participation for genetic material retention is optional. Genetic information may be shared broadly in a coded form for future genetic research or analysis. This genetic information will NOT be used for genomic data sharing with genome-wide association studies. The genetic analysis which will be limited to the set of participants recruited to this study. The specimens may be used by our University of California, San Francisco (UCSF) research team for studies on diabetes, cardiovascular disease, liver disease, and other aspects of metabolism.

MeSH Terms

Conditions

Sleep Apnea, ObstructiveHypoxiaInsulin Resistance

Interventions

Continuous Positive Airway Pressure

Condition Hierarchy (Ancestors)

Sleep Apnea SyndromesApneaRespiration DisordersRespiratory Tract DiseasesSleep Disorders, IntrinsicDyssomniasSleep Wake DisordersNervous System DiseasesSigns and Symptoms, RespiratorySigns and Symptoms

Study Officials

Jean-Marc Schwarz, PhD
University of California, San Francisco
PRINCIPAL INVESTIGATOR
Andrew Krystal, MD
University of California, San Francisco
PRINCIPAL INVESTIGATOR

Enrollment

48 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: CASE ONLY
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

October 2, 2018

First Posted

October 4, 2018

Study Start

October 31, 2018

Actual (reported)

Tissue-specific Insulin Resistance in Obstructive Sleep Apnea: Role of Hypoxia

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (2)

Secondary Outcomes (2)

Study Arms (2)

OSA with hypoxia

OSA without hypoxia

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Biospecimen

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Intervention Hierarchy (Ancestors)

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (2)

Secondary Outcomes (2)

Study Arms (2)

OSA with hypoxia

OSA without hypoxia

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Biospecimen

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Intervention Hierarchy (Ancestors)

Data Sharing

Source record

Locations